{{news release|date=December 2012}}
'''Autologous Patient Specific Tumor Antigen Response''' technology, or apSTAR, is a new [[cancer]] treatment procedure being developed by [[IMULAN BioTherapeutics, LLC]] and [http://www.VetCancer.com Veterinary Cancer Therapeutics, LLC] for comparative [[oncology]].

Also known as laser-assisted [[immunotherapy]], apSTAR is an [[experimental cancer treatment]] for solid [[tumor]]s that utilizes an [[autologous]] [[vaccine]]-like approach to stimulate [[immune response]]s. Specifically, [[laser]]-assisted [[immunotherapy]] combines laser-induced ''[[in situ]]'' [[tumor]] devitalization with an immuno[[adjuvant]] for local [[immunostimulation]]. 

Experimental data and initial human trials suggests that laser-assisted immunotherapy treatment may prolong life and even cure patients with advanced cancer.<ref>{{cite journal |author=Song S, Zhou F, Nordquist RE, Carubelli R, Liu H, Chen WR |title=Glycated chitosan as a new non-toxic immunological stimulant |journal=Immunopharmacol Immunotoxicol |volume=31 |issue=2 |pages=202–8 |year=2009 |month=June |pmid=19514994 |doi=10.1080/08923970802629593 |url=http://informahealthcare.com/doi/abs/10.1080/08923970802629593}}</ref><ref>{{cite journal |author=Chen WR, Huang Z, Korbelik M, Nordquist RE, Liu H |title=Photoimmunotherapy for cancer treatment |journal=J. Environ. Pathol. Toxicol. Oncol. |volume=25 |issue=1-2 |pages=281–91 |year=2006 |pmid=16566724 |url=http://www.begellhouse.com/journals/0ff459a57a4c08d0,5d84548f012e18bf,46b895bf003d47ae.html}}</ref><ref>{{cite journal |author=Chen WR, Korbelik M, Bartels KE, Liu H, Sun J, Nordquist RE |title=Enhancement of laser cancer treatment by a chitosan-derived immunoadjuvant |journal=Photochem. Photobiol. |volume=81 |issue=1 |pages=190–5 |year=2005 |pmid=15535737 |doi=10.1562/2004-07-20-RA-236 |url=http://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0031-8655&date=2005&volume=81&issue=1&spage=190}}</ref><ref>{{cite journal |author=Chen WR, Carubelli R, Liu H, Nordquist RE |title=Laser immunotherapy: a novel treatment modality for metastatic tumors |journal=Mol. Biotechnol. |volume=25 |issue=1 |pages=37–44 |year=2003 |month=September |pmid=13679633 |doi=10.1385/MB:25:1:37 }}</ref><ref>{{cite journal |author=Chen WR, Liu H, Ritchey JW, Bartels KE, Lucroy MD, Nordquist RE |title=Effect of different components of laser immunotherapy in treatment of metastatic tumors in rats |journal=Cancer Res. |volume=62 |issue=15 |pages=4295–9 |year=2002 |month=August |pmid=12154032 |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=12154032}}</ref><ref>{{cite journal |author=Chen WR, Zhu WG, Dynlacht JR, Liu H, Nordquist RE |title=Long-term tumor resistance induced by laser photo-immunotherapy |journal=Int. J. Cancer |volume=81 |issue=5 |pages=808–12 |year=1999 |month=May |pmid=10328237 |doi=10.1002/(SICI)1097-0215(19990531)81:5<808::AID-IJC23>3.0.CO;2-J}}</ref><ref>{{cite journal |author=Chen WR, Adams RL, Carubelli R, Nordquist RE |title=Laser-photosensitizer assisted immunotherapy: a novel modality for cancer treatment |journal=Cancer Lett. |volume=115 |issue=1 |pages=25–30 |year=1997 |month=May |pmid=9097975 |url=http://linkinghub.elsevier.com/retrieve/pii/S0304-3835(97)04707-1 |doi=10.1016/S0304-3835(97)04707-1}}</ref>

==Principles of apSTAR==
The two principles underlying apSTAR are: (1) local destruction of tumor by means of a laser combined with a photo-absorbing dye; and (2) stimulated immune response due to the application of an [[immunoadjuvant]], but also due to increases in antigen accessibility caused by the destruction of the tumor. Both elements of this protocol are crucial. It is important to note that since this method independently triggers the immune response in each individual, it does not depend upon [[cross reactivity]] in the expression of [[tumor-specific antigen]] between hosts (as is required in conventional antibody immunotherapy and vaccination.)

==Trials==
Veterinary Cancer Therapeutics, LLC a subsidiary of [[IMULAN BioTherapeutics, LLC]] is in exploratory trials for canine [[osteosarcoma]], canine [[melanoma]], canine and feline [[fibrosarcoma]], and several other forms of cancer.<ref>http://www.IMULAN.com</ref>

==References==
{{reflist}}

{{DEFAULTSORT:Autologous Patient Specific Tumor Antigen Response}}
[[Category:Cancer treatments]]